RT Journal Article
SR Electronic
T1 Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.13.23285861
DO 10.1101/2023.02.13.23285861
A1 Hjaltelin, Jessica Xin
A1 Novitski, Sif Ingibergsdóttir
A1 Jørgensen, Isabella Friis
A1 Johansen, Julia Sidenius
A1 Chen, Inna M
A1 Siggaard, Troels
A1 Vulpius, Siri
A1 Jensen, Lars Juhl
A1 Brunak, Søren
YR 2023
UL http://medrxiv.org/content/early/2023/02/16/2023.02.13.23285861.abstract
AB Pancreatic cancer is one of the deadliest cancer types with poor treatment options. Better detection of early symptoms and relevant disease correlations could improve pancreatic cancer prognosis. In this retrospective study, we used symptom and disease codes (ICD-10) from the Danish National Patient Registry (NPR) encompassing 8.1 million patients from 1977 to 2018, of whom 22,727 were diagnosed with pancreatic cancer. To complement and compare these diagnosis codes with deeper clinical data, we used a text mining approach to extract symptoms from free text clinical notes in electronic health records (4,418 pancreatic cancer patients and 44,180 controls). We used both data sources to generate and compare symptom disease trajectories to uncover temporal patterns of symptoms prior to pancreatic cancer diagnosis for the same patients. We show that the text mining of the clinical notes was able to capture richer statistically significant symptom patterns, in particular general pain, abdominal pain, and liver-related conditions. We also detected haemorrhages (p-value = 4.80 · 10-08) and headache (p-value = 2.12 ·10-06) to be linked as early symptoms of pancreatic cancer. Chaining symptoms together in trajectories identified patients with jaundice conditions having higher median survival (>90 days) compared to patients following trajectories that included haemorrhage, oedema or anaemia (≤90 days). Additionally, we discovered a group of cardiovascular patients that developed pancreatic cancer with a lower median survival (≤90 days). These results provide an overview of two types of pancreatic cancer symptom trajectories. The two approaches and data types complement each other to provide a fuller picture of the early risk factors for pancreatic cancer.Competing Interest StatementS.B. reports ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK-Abello A/S and managing board memberships in Proscion A/S and Intomics A/S outside the submitted work. I.M.C. reported receiving research funding and hotel/airfare reimbursement to attend global health meetings from Roche, BMS, Celgene, Genis, and an advisory relationship with Amgen and AstraZeneca. L.J.J. reports ownerships in Amgen Inc, AstraZeneca PLC and Novo Nordisk A/S. All other authors declare no competing interests.Clinical TrialThis is not a clinical trialFunding StatementWe would like to acknowledge funding from the Novo Nordisk Foundation (grant agreements NNF14CC0001 and NNF17OC0027594), the Braindrugs (R279-2018-1145) as well as the Danish Innovation Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work was approved as a registry study that does not require ethical permissions in Denmark as well as patient consent. Access to the data was approved by the Danish Data Protection Agency (ref: 514-0255/18-3000, 514-0254/18-3000, SUND-2016-50), the Danish Health Data Authority (ref: FSEID-00003724 and FSEID-00003092), and the Danish Patient Safety Authority (3-3013-1731/1/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPermission to access the person-sensitive data used for this study can be obtained through the Danish Data Protection Agency, the Danish Health Authority, and the Danish Health regions (Capital Region and Region Zealand). Due to the sensitivity of these patient data, we have only provided diagnosis and co-occurrence information when grouped to at least five patients. All patient information published here is non-person-sensitive summary level data.